Navigation Links
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Date:1/14/2008

an Orphan Medicinal Product in the EU for the treatment of MDS, which, if approved, entitles the drug to ten years of market exclusivity for the approved indication. Vidaza has also been designated as an Orphan Medicinal Product in the EU for the treatment of acute myeloid leukemia (AML).

The application is based upon clinical data which includes the results from the Company's Phase 3 multi-center, international, randomized study of Vidaza(R) (azacitidine for injection) in the treatment of patients with higher-risk MDS. The primary objective of this Phase 3 trial was to demonstrate superiority in overall survival of Vidaza versus CCR. The study included 358 patients at sites in the U.S., Europe, and Australia. At baseline, approximately 90 percent of patients were considered to have higher- risk MDS, based on subsequent independent review of FAB subtypes or IPSS classification. Patients were assigned to treatment with Vidaza (N=179; 75 mg/m2/day SC for seven consecutive days every 28 days) or CCR. Patients assigned to CCR could receive either BSC alone (N=105), low-dose cytarabine (LDAC; N=49), or standard chemotherapy (Std Chemo; N=25). The median number of cycles for Vidaza was nine; the median number of cycles for the CCR arm was as follows: BSC seven cycles, LDAC 4.5 cycles and Std Chemo one cycle.

With a median follow-up of 21.1 months, Vidaza demonstrated a statistically significant overall survival advantage over CCR (24.4 months vs. 15 months; stratified log rank p=0.0001).The hazard ratio describing this treatment effect was 0.58 (95 percent confidence interval of 0.43 to 0.77). At two years, Vidaza demonstrated a two-fold advantage in overall survival over CCR (51 percent vs. 26 percent; log rank p<0.0001). Among patients with poor cytogenetic profiles (as defined by IPSS, 28 percent of enrolled patients), median survival was 17.2 months in the Vidaza arm, compared to six months in the CCR arm (log rank p=0.01). Forty-five percent of transfu
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
2. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
3. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
4. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
5. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
6. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
7. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
8. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio ... acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... of the acquisition were not disclosed. Progressive ... a wide range of sleep, mobility, and respiratory products to ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Care Group has become a pioneering educational member of ... ISVH,s primary aim is the achievement of high levels ... a whole. , Educational members of ISVH promote the ... protocols and recommendations for blood pressure monitoring to achieve ...
... Oct. 5 Kimberly-Clark Corporation (NYSE: ... Medical Company,s pain management business, which includes a number ... Care business has been the exclusive distributor of Baylis ... , The acquisition improves the competitive position of ...
Cached Medicine Technology:Fora Care Group Becomes Pioneering Educational Member of the International Society of Vascular Health 2Fora Care Group Becomes Pioneering Educational Member of the International Society of Vascular Health 3Fora Care Group Becomes Pioneering Educational Member of the International Society of Vascular Health 4Kimberly-Clark Acquires Baylis Medical Company's Pain Management Business 2Kimberly-Clark Acquires Baylis Medical Company's Pain Management Business 3
(Date:7/9/2014)... at the Perelman School of Medicine at the University ... Institute have received an $8 million grant from the ... photodynamic light therapy (PDT) in patients with malignant pleural ... often manifests itself in the lining of the lungs ... The grant will fund a clinical trial and additional ...
(Date:7/9/2014)... signals active in almost all types of cancer sends ... may help fuel a tumour,s uncontrolled growth, new research ... London, identified a molecular trigger responsible for ratcheting up ... factory that makes the building blocks cancer cells need ... signalling pathway, called SREBP, controls the flow of messages ...
(Date:7/9/2014)... lung cancer, researchers have uncovered mutations in a cell-signaling ... new knowledge may expand treatments for patients because drugs ... or are in clinical trials. , Reporting July 9 ... Atlas (TCGA), including researchers at Washington University School of ... institutions, studied tumors from 230 patients with lung adenocarcinoma. ...
(Date:7/9/2014)... Cancer Center paint a relatively optimistic picture of women,s ... have spread to the chest wall or skin, but ... skin, regardless of size and whether they have involved ... and called "locally advanced" tumors, suggesting that they are ... survival. Locally advanced breast cancers of this and other ...
(Date:7/9/2014)... drug users in Russia might contribute to HIV ... conducted by researchers from Boston University Schools of ... Petersburg Pavlov State University, sought to discover the ... of a cohort of HIV-positive people with lifetime ... arrested by police were more likely to share ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2
... today that it has entered into a multi-year, sole-source supply agreement ... formulas and growing-up milks produced by Lactalis and sold in France ... ... 2009 - Martek Biosciences Corporation (NASDAQ: MATK) announced today ...
... 14 The U.S. Senate Finance Committee, in ... questions about how its plan to require all ... tax penalties will provide affordable health care, said ... letter to Senator Baucus here: ...
... Ga., May 14, 2009 The AMERIGROUP Foundation today ... principal of Seaborn Lee Elementary School, by designating her ... Seaborn Lee for more than six years. After noticing ... from health issues, Dr. Massey decided to take action. ...
... trump environment as the primary reason that some adolescents ... crime, according to groundbreaking research led by distinguished criminologist ... , The study is believed to be the first ... "Victimization can appear to be a purely environmental phenomenon, ...
... that it has partnered with Emergency Physicians Affiliates in San Antonio, ... five emergency departments. , ... Cerritos, CA and San ... announced today that it has partnered with Emergency Physicians Affiliates in ...
... Myers President, Campaign for Tobacco-Free KidsWASHINGTON, May 14 ... health and the public,s right to breathe clean air ... all restaurants and bars, smoke-free. Gov. Jim Doyle has ... the bill, which would make Wisconsin the 27th state ...
Cached Medicine News:Health News:Martek Signs Sole-Source ARA Supply Agreement with Lactalis Nutrition Sante 2Health News:Martek Signs Sole-Source ARA Supply Agreement with Lactalis Nutrition Sante 3Health News:Sen. Max Baucus: Answer 10 Questions About Mandatory Purchase of Health Insurance Including Why the Public Was Excluded From Today's Committee Meeting 2Health News:Sen. Max Baucus: Answer 10 Questions About Mandatory Purchase of Health Insurance Including Why the Public Was Excluded From Today's Committee Meeting 3Health News:Sen. Max Baucus: Answer 10 Questions About Mandatory Purchase of Health Insurance Including Why the Public Was Excluded From Today's Committee Meeting 4Health News:Sen. Max Baucus: Answer 10 Questions About Mandatory Purchase of Health Insurance Including Why the Public Was Excluded From Today's Committee Meeting 5Health News:Dr. Emily Abrams Massey of Atlanta Honored as 'Healthy Hero' by the AMERIGROUP Foundation 2Health News:For adolescent crime victims, genetic factors play lead role 2Health News:Marina Medical Expands into Texas with Five Emergency Departments in San Antonio 2Health News:Approval of Wisconsin Smoke-Free Legislation Is Historic Win for Health 2
... simple intuitive programming and almost completely noiseless ... personal cycler in the modern laboratory workplace. ... self-adjusting heated lid allows a choice of ... a microplate of 5 x 5 in ...
... 96 temperature cyclers, the gradient block can be ... up to 14 or 22 across the 40- ... of up to 2C between adjacent wells in ... to 12 different annealing temperatures in a single ...
... includes: Mx3005P instrument and custom filter ... (5) filters. The standard filter set ... (535nm-555nm), ROX/Texas Red (585nm-610nm), Cy5 (635nm-665nm) ... computer, Mx3005P analysis software, Beacon Designer ...
... The SmartCycler System is a rapid, ... from prepared biological samples. By automating much ... reaction site individually programmable, it is the ... system now on the market. The SmartCycler ...
Medicine Products: